Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...
A research team at Memorial Sloan Kettering Cancer Center (MSK) has made new insights into how the body forms immune cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback